Stockreport

Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting

Kairos Pharma, Ltd.  (KAPA) 
PDF Interim efficacy analysis highlights potential value of combination therapy of ENV-105 and apalutamide following positive safety data LOS ANGELES--(BUSINESS WIRE)--Ka [Read more]